169 related articles for article (PubMed ID: 30245624)
21. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3.
Lipina TV; Kaidanovich-Beilin O; Patel S; Wang M; Clapcote SJ; Liu F; Woodgett JR; Roder JC
Synapse; 2011 Mar; 65(3):234-48. PubMed ID: 20687111
[TBL] [Abstract][Full Text] [Related]
22. Disrupted in schizophrenia 1 (DISC1) L100P mutants have impaired activity-dependent plasticity in vivo and in vitro.
Tropea D; Molinos I; Petit E; Bellini S; Nagakura I; O'Tuathaigh C; Schorova L; Mitchell KJ; Waddington J; Sur M; Gill M; Corvin AP
Transl Psychiatry; 2016 Jan; 6(1):e712. PubMed ID: 26756905
[TBL] [Abstract][Full Text] [Related]
23. Caveolin-1 regulation of disrupted-in-schizophrenia-1 as a potential therapeutic target for schizophrenia.
Kassan A; Egawa J; Zhang Z; Almenar-Queralt A; Nguyen QM; Lajevardi Y; Kim K; Posadas E; Jeste DV; Roth DM; Patel PM; Patel HH; Head BP
J Neurophysiol; 2017 Jan; 117(1):436-444. PubMed ID: 27832597
[TBL] [Abstract][Full Text] [Related]
24. Alteration of Neuronal Excitability and Short-Term Synaptic Plasticity in the Prefrontal Cortex of a Mouse Model of Mental Illness.
Crabtree GW; Sun Z; Kvajo M; Broek JA; Fénelon K; McKellar H; Xiao L; Xu B; Bahn S; O'Donnell JM; Gogos JA
J Neurosci; 2017 Apr; 37(15):4158-4180. PubMed ID: 28283561
[TBL] [Abstract][Full Text] [Related]
25. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
Weiner I
Psychopharmacology (Berl); 2003 Sep; 169(3-4):257-97. PubMed ID: 12601500
[TBL] [Abstract][Full Text] [Related]
26. Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits.
Trossbach SV; Bader V; Hecher L; Pum ME; Masoud ST; Prikulis I; Schäble S; de Souza Silva MA; Su P; Boulat B; Chwiesko C; Poschmann G; Stühler K; Lohr KM; Stout KA; Oskamp A; Godsave SF; Müller-Schiffmann A; Bilzer T; Steiner H; Peters PJ; Bauer A; Sauvage M; Ramsey AJ; Miller GW; Liu F; Seeman P; Brandon NJ; Huston JP; Korth C
Mol Psychiatry; 2016 Nov; 21(11):1561-1572. PubMed ID: 26754951
[TBL] [Abstract][Full Text] [Related]
27. Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia.
Scarduzio M; Zimmerman CN; Jaunarajs KL; Wang Q; Standaert DG; McMahon LL
Exp Neurol; 2017 Sep; 295():162-175. PubMed ID: 28587876
[TBL] [Abstract][Full Text] [Related]
28. Epistatic and Independent Effects on Schizophrenia-Related Phenotypes Following Co-disruption of the Risk Factors Neuregulin-1 × DISC1.
O'Tuathaigh CM; Fumagalli F; Desbonnet L; Perez-Branguli F; Moloney G; Loftus S; O'Leary C; Petit E; Cox R; Tighe O; Clarke G; Lai D; Harvey RP; Cryan JF; Mitchell KJ; Dinan TG; Riva MA; Waddington JL
Schizophr Bull; 2017 Jan; 43(1):214-225. PubMed ID: 27613806
[TBL] [Abstract][Full Text] [Related]
29. Social defeat interacts with Disc1 mutations in the mouse to affect behavior.
Haque FN; Lipina TV; Roder JC; Wong AH
Behav Brain Res; 2012 Aug; 233(2):337-44. PubMed ID: 22659396
[TBL] [Abstract][Full Text] [Related]
30. Serotonin 5-HT
Gener T; Tauste Campo A; Alemany-González M; Nebot P; Delgado-Sallent C; Chanovas J; Puig MV
Neuropharmacology; 2019 Nov; 158():107743. PubMed ID: 31430459
[TBL] [Abstract][Full Text] [Related]
31. Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors.
Calabresi P; Saiardi A; Pisani A; Baik JH; Centonze D; Mercuri NB; Bernardi G; Borrelli E
J Neurosci; 1997 Jun; 17(12):4536-44. PubMed ID: 9169514
[TBL] [Abstract][Full Text] [Related]
32. Bidirectional Regulation of Hippocampal Synaptic Plasticity and Modulation of Cumulative Spatial Memory by Dopamine D2-Like Receptors.
Caragea VM; Manahan-Vaughan D
Front Behav Neurosci; 2021; 15():803574. PubMed ID: 35095441
[TBL] [Abstract][Full Text] [Related]
33. Disrupted-in-schizophrenia 1 regulates transport of ITPR1 mRNA for synaptic plasticity.
Tsuboi D; Kuroda K; Tanaka M; Namba T; Iizuka Y; Taya S; Shinoda T; Hikita T; Muraoka S; Iizuka M; Nimura A; Mizoguchi A; Shiina N; Sokabe M; Okano H; Mikoshiba K; Kaibuchi K
Nat Neurosci; 2015 May; 18(5):698-707. PubMed ID: 25821909
[TBL] [Abstract][Full Text] [Related]
34. The Altered Supramolecular Structure of Dopamine D2 Receptors in Disc1-deficient Mice.
Onishi T; Sakamoto H; Namiki S; Hirose K
Sci Rep; 2018 Jan; 8(1):1692. PubMed ID: 29374282
[TBL] [Abstract][Full Text] [Related]
35. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.
Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
Neuropsychopharmacology; 2006 Sep; 31(9):1991-2001. PubMed ID: 16738543
[TBL] [Abstract][Full Text] [Related]
36. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2009 Mar; 12(2):227-41. PubMed ID: 18687163
[TBL] [Abstract][Full Text] [Related]
37. Disruption of exploratory and habituation behavior in mice with mutation of DISC1: an ethologically based analysis.
Walsh J; Desbonnet L; Clarke N; Waddington JL; O'Tuathaigh CM
J Neurosci Res; 2012 Jul; 90(7):1445-53. PubMed ID: 22388794
[TBL] [Abstract][Full Text] [Related]
38. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.
Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC
Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782
[TBL] [Abstract][Full Text] [Related]
39. Disrupted-in-Schizophrenia 1 (DISC1) Overexpression and Juvenile Immune Activation Cause Sex-Specific Schizophrenia-Related Psychopathology in Rats.
Uzuneser TC; Speidel J; Kogias G; Wang AL; de Souza Silva MA; Huston JP; Zoicas I; von Hörsten S; Kornhuber J; Korth C; Müller CP
Front Psychiatry; 2019; 10():222. PubMed ID: 31057438
[TBL] [Abstract][Full Text] [Related]
40. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment.
Weiner I; Arad M
Behav Brain Res; 2009 Dec; 204(2):369-86. PubMed ID: 19433114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
